Radioligand therapy (RLT) targets cancer cells with radiation while minimizing impact on surrounding healthy tissue. In this episode of JNM Podcast, our panelists discuss training, access, production capacity, and everything else that is necessary to make RLT more widely available to the patients who need it.

Moderator: Ken Herrmann, MD (Universitätsmedizin, Essen, Germany). 
Panelists: Andrei Iagaru, MD (Stanford University Medical Center, Stanford, California), Leonhard Schaetz (Novartis, Basel, Switzerland), and Désirée Deandreis, MD (Gustave Roussy, Villejuif, France).

Sponsored by SOFIE Biosciences (https://sofie.com)